HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their...